|
| TZD | Additional compound | Model | Effect | Reference |
|
| | Gamma-radiation | Lung carcinoma cell lines (A549, H460) | DNA damage, apoptosis | [124] |
| | RXR- ligands (SR11237, 6-OH-11-O-hydroxyphenanthrene) | Breast carcinoma cell line (MDA-MB231), lung carcinoma cell line (Calu-3), glioblastoma cell line (U87MG), melanoma cell line (G361) | Growth inhibition; apoptosis | [125–127] |
| CIGLI | TNF--related apoptosis inducing ligand | Ovarian cancer cell line (HEY) | Decrease of proliferation | [128] |
| | Lovastatin | Pancreatic carcinoma cell lines (Panc02, MIA, PACa-2), breast carcinoma cell lines (EMT6, MDA-MB-316), colon cancer cell line (C26) | Decrease of cell viability; decrease of proliferation | [129] |
| | Phenylbutyrate | Lung carcinoma cell lines (A549, H157) | Growth inhibition | [130] |
|
| | 9-cis retinoic acid | Gastric carcinoma cell line (SGC7901) | Apoptosis | [131] |
| | Cisplatin | Lung cancer cell lines (A549, H522); mesotheloma cell line (EHMES-10) | Growth inhibition | [87, 132] |
| | Paclitaxel | Lung carcinoma cell lines (A549, H522) | Growth inhibition | [132] |
| | RXR- ligands (bexarotene, all-trans retinoic acid) | Breast cancer cell lines (MCF-7, T-47D, ZR-75-1) | Growth inhibition | [133] |
| TRO | Cell signalling molecules (TRAIL, heregulin) | Ovarian cancer cell line (HEY); breast cancer cell lines (MCF-7, SKBR-3, MDA-MB-453) | Decrease of cell number; apoptosis | [128, 134] |
| | Lovastatin | Glioblastoma cell line (DBTRG05MG), lung cancer cell line (CL1-0) | Cell cycle inhibitor expression | [135] |
| | Aspirin | Lung cancer cell lines (CL1-0, A549) | Decrease of proliferation | [136] |
| | Tamoxifen | Breast cancer cell line (MCF-7) | Growth inhibition | [137] |
| | X-rays | Cervix cancer cell lines (HeLa, Me180) | Decrease of cell viability | [138] |
|
| | Platinium-based compounds (cisplatin, carboplatin) | Ovarian cancer cell lines (OVCA420, OVCA429, ES), lung cancer cell lines (A549, Calu-1, H23, H596, H1650) | Growth inhibition | [85] |
| | 5-Fluorouracil | Hepatoma cell lines (BEL7402, Huh-7); colon cancer cell line (HT-29) | Decrease of cell viability, apoptosis | [82, 139] |
| | RXR- ligands (bexarotene, 9-cis retinoic acid) | Breast cancer cell lines (MCF-7TR1, SKBR-3, T47D), colon cancer cell line (Moser) | Increase of differentiation, growth inhibition; decrease of cell viability | [80, 140] |
| ROSI | Cell signalling molecules (TNF-, anti-Fas IgM, Seliciclib) | Breast cancer cell line (MDA-MB-231) | Growth inhibition | [141] |
| Gemcitabine | Pancreas cancer cell lines (PANC-1, Panc02) | Decrease of cell viability, growth inhibition | [142] |
| | Gefitinib | Lung cancer cell line (A549) | Growth inhibition | [83] |
| | Herceptin | Breast cancer cell line (MCF-7) | Growth inhibition | [84] |
| | Bortezomib | Melanoma cell lines (MV3, FemX-1, G361) | Growth inhibition | [143] |
|
| | Paclitaxel | Lung cancer cell lines (A549, H522) | Growth inhibition | [132] |
| | RXR- ligands (LG268) | Liposarcoma cells (primary) | Increase of differentiation | [81] |
| PIO | Statins (Simvastin, lovastatin) | Glioblastoma cell lines (U87, U138, LN405, RGII); meningeoma cell lines (IOMM-Lee, KT21-MG1) | Decrease of cell viability | [144, 145] |
| | Gemcitabine | Pancreas cancer cell line (PANC-1) | Decrease of cell viability | [142] |
| | 2-Deoxyglucose | Prostate cancer cell lines (PC-3, LNCaP) | Decrease in tumor spheroid formation | [146] |
|
| EFA | Paclitaxel | Anaplastic thyroid carcinoma cell lines (DRO, BHT-101, ARO) | Growth inhibition | [88] |
|
